SEC Form 4 · accession 0001181431-15-004307
ARROWHEAD PHARMACEUTICALS, INC. · ARWR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Richard Anzalone
Officer — President and CEO · Director
Period of report
Mar 4, 2015
Accepted (ET)
Mar 6, 2015 · 8:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000879407
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 4, 2015 | A | 360,000 | $0.00 | A | 620,173 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF2,F3,F4 | $7.75 | Mar 6, 2015 | A | 300,000 | A | — | Mar 6, 2025 | Common Stock | 300,000 | 1,086,466 | D |
Explanation of responses
- F1Represents the maximum number of shares underlying a restricted stock unit that may be earned based on the achievement of certain predetermined performance goals related to the advancement of the Company's clinical programs and business development over three to five years. If the performance goals are not met within the required time periods, the award will be forfeited in part or in whole.
- F2Represents the maximum number of shares issuable pursuant to the stock option grant that vest based on the achievement of certain predetermined goals related to the advancement of the Company's clinical programs and business development over three to five years. If the performance goals are not met within the required time periods, the award will be forfeited in part or in whole.
- F3Vests and become exercisable over a three to five year period if performance goals are met.
- F4Stock option has a maximum ten year term, but may expire earlier if performance goals are not met.